US Obesity Prevalence: CDC State and Demographic Data
About 4 in 10 American adults have obesity. That is not a niche health issue. Yet many people who could be evaluated for medical treatment never are. The gap between need and care is wide, and it is the reason a lot of people end up researching options on their own.
This page summarizes recent CDC and NHANES data on obesity prevalence: who is most affected, where rates are highest, and the costs and health effects of obesity. It is meant as a reference for people researching their own situation, and as context for why access to weight management care matters.
National Obesity Prevalence Data
The most recent National Health and Nutrition Examination Survey (NHANES) results, covering August 2021 to August 2023, found that 40.3% of US adults had obesity, defined as a BMI of 30 or higher[1]. NHANES measures height and weight directly rather than relying on self-report. The most recent overweight figure NIDDK reports is from 2017-2018, when 30.7% of adults had overweight (BMI 25 to 29.9) and 42.4% had obesity, about 73% combined[3].
Severe obesity, a BMI of 40 or higher, affected 9.4% of adults in 2021-2023[1]. It is the category that has grown fastest in recent years.
The Upward Trend: Severe Obesity Has Doubled Since 2000
Obesity in the United States has risen substantially over the past quarter century. According to NHANES data, adult obesity prevalence was 30.5% in 1999-2000 and 42.4% in 2017-2018[2]. Over the same period, severe obesity roughly doubled, from 4.7% to 9.2%[2].
The most recent data shows a plateau in overall obesity but not in severe obesity. CDC reported that age-adjusted obesity prevalence did not change significantly between 2013-2014 and August 2021 to August 2023, while age-adjusted severe obesity rose from 7.7% to 9.7%[1]. In other words, the distribution of body weight has shifted, with more adults in the highest weight category.
Who Is Most Affected: Demographics
Obesity is not evenly distributed across groups. Knowing who is most affected helps explain public health priorities, where access barriers are greatest, and why some people wonder whether treatment is “for them.”
By Sex
In 2021-2023, 39.2% of men and 41.3% of women had obesity, a difference that was not statistically significant[1]. Severe obesity showed a clear gap: 12.1% of women compared with 6.7% of men, and women had higher rates than men in every age group[1]. Hormonal transitions such as perimenopause and menopause can affect weight in women, though overall obesity prevalence is similar between the sexes.
By Age
Obesity prevalence is highest in middle age. In 2021-2023, 46.4% of adults aged 40 to 59 had obesity, compared with 35.5% of adults aged 20 to 39 and 38.9% of adults aged 60 and older[1]. Severe obesity followed the same pattern, peaking at 12.0% among adults aged 40 to 59[1]. Longer exposure to weight-promoting environments, metabolic changes with age, and hormonal transitions such as perimenopause can all play a part.
By Race and Ethnicity
Obesity prevalence differs by race and ethnicity, and these differences are part of the broader picture of health equity.
In the 2017-2018 NHANES, obesity prevalence was 49.6% among non-Hispanic Black adults, 44.8% among Hispanic adults, 42.2% among non-Hispanic white adults, and 17.4% among non-Hispanic Asian adults[2]. Among women, prevalence was highest in non-Hispanic Black women, at 56.9%[2].
These disparities are not the result of individual behavior. They reflect structural factors: access to affordable, nutritious food; safe places to be active; healthcare quality and trust; chronic stress; and the effects of systemic inequality. Talking about who has obesity means also talking about why.
By Education Level
Obesity prevalence is lower among adults with more formal education. In 2021-2023, 31.6% of adults with a bachelor’s degree or more had obesity, compared with 45.0% of adults with some college and 44.6% of adults with a high school diploma or less[1]. Education often tracks with income, which affects access to food, places to be active, and healthcare. The relationship reflects access, not just individual knowledge.
State-by-State Variation
Obesity prevalence varies by state. The variation reflects differences in food environment, built environment (sidewalks, parks, fitness facilities), healthcare access, income, and other factors.
State figures come from a different CDC survey than the national figures above. The Behavioral Risk Factor Surveillance System (BRFSS) is a telephone survey that uses self-reported height and weight, which tends to produce lower obesity estimates than NHANES measurements. The figures below are from 2025 BRFSS data, published by CDC in September 2026[4].
States with the Lowest Obesity Rates
In 2025, Colorado had the lowest adult obesity prevalence among states, at 25.7%, followed by Hawaii (26.4%), Massachusetts and New Jersey (27.0% each), and New York (28.5%). The District of Columbia was lower still, at 24.2%[4]. Even in these states, about 1 in 4 adults has obesity. By region, the Northeast (29.6%) and the West (30.7%) had the lowest prevalence[4].
States with the Highest Obesity Rates
In 2025, the states with the highest adult obesity prevalence were Alabama (39.7%), North Dakota (39.1%), Kentucky (38.8%), Oklahoma (38.1%), and Tennessee (37.9%)[4]. Twenty-one states had a prevalence of 35% or higher, and no state reached 40%. By region, the Midwest (35.5%) and the South (34.8%) had the highest prevalence. CDC reported insufficient data for California, Mississippi, and Nevada in 2025, so those states do not appear in the rankings[4].
These patterns are not random. Regional differences track with income, food access, access to preventive care, and other structural factors. Seeing obesity as a public health problem means looking at the conditions that make some places more affected than others.
Health Impact and Disease Association
Obesity is a medical condition that raises the risk of several serious chronic diseases. These are physiological effects, not moral ones. According to NIDDK, overweight and obesity may increase the risk of[5]:
- Type 2 diabetes
- High blood pressure
- Heart disease
- Stroke
- Metabolic syndrome
- Fatty liver diseases
- Some cancers
- Osteoarthritis
The link between obesity and these conditions is not about willpower or discipline. It is biological. Fat tissue is metabolically active: it releases inflammatory signals, affects how the body responds to insulin, and disrupts hormonal regulation.
Economic Impact
The medical costs linked to obesity are substantial. A 2021 study cited by CDC estimated that obesity was associated with about 172.7 billion dollars in excess annual medical spending among US adults, in 2019 dollars[6]. These costs show up across the healthcare system: hospital stays, emergency visits, office visits, medications, and care for obesity-related complications.
The same study estimated that adults with obesity had about 1,861 dollars in higher annual medical costs per person than adults at a healthy weight, and adults with severe obesity about 3,097 dollars more (2019 dollars)[6]. Those costs fall both on individuals and on the healthcare system.
The Treatment Gap: Why So Few People Receive Care
Despite how common obesity is and how much it affects health and costs, many adults who could be evaluated for medical treatment never are. That gap is one of the defining features of obesity care in the United States.
Why the Gap Exists
Several overlapping barriers drive the treatment gap.
Cost and insurance coverage: Many insurance plans do not cover weight management medications, or cover them only for people who meet specific BMI and health criteria. People without coverage face the full cost of medication and provider visits. Prices vary by medication, dose, and program, so compare the total cost: medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms.
Provider familiarity and stigma: Many primary care providers do not regularly prescribe weight management medications. The idea that obesity is a personal failure rather than a medical condition has shaped medical training and practice. People can encounter stigma in clinical settings, which discourages them from seeking care.
Geographic access: Obesity medicine specialists are concentrated in larger cities. People in rural communities may have few providers trained in weight management nearby, and travel can make specialist care impractical.
Appointment availability and wait times: Some weight management programs and specialty clinics have waitlists, and new patients may wait before they are seen.
Lack of awareness: Many adults with obesity do not know medical treatment is an option. The conversation has long centered on diet and exercise as the only “legitimate” approaches, even for people who have tried them repeatedly.
These are systemic barriers, not individual failures, and they fall hardest on people with lower incomes, people without insurance, people in rural areas, and communities of color.
The Role of GLP-1 Medications in Closing the Gap
GLP-1 medications reduce appetite and slow stomach emptying. Two are FDA-approved for chronic weight management: Wegovy (semaglutide) and Zepbound (tirzepatide). Each is approved, along with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or in adults with overweight and at least one weight-related condition[7][8]. A licensed provider decides whether a prescription is appropriate.
These medications carry real risks. Both labels include a boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[7][8]. The most common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain[7][8]. Other warnings on the labels include pancreatitis, gallbladder problems, and kidney injury from dehydration. Results vary from person to person.
Cost is the main barrier for many uninsured and underinsured people. Some telehealth programs offer brand-name medication through manufacturer self-pay options, and some prescribe compounded semaglutide or tirzepatide. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency. The FDA does not review compounded medications for safety, effectiveness, or quality.
How Telehealth Addresses Access Barriers
Telehealth programs can reduce some of the barriers above, though programs differ a great deal in what they include and what they cost:
Geography: At most telehealth programs, you complete a health history online, and a licensed provider reviews it, sometimes with a video visit, before deciding whether a prescription is appropriate. If one is written, a licensed pharmacy fills it and ships it to you. Some programs require a live video visit in certain states, so ask the program what applies where you live. Ask whether the provider is licensed in your state.
Cost and insurance: Some programs bundle provider visits with medication; others bill for medication, visits, and labs separately. Ask exactly what the monthly fee covers, how the price changes as the dose increases, and how to cancel.
Appointment availability: Online intake can shorten the wait compared with a specialist clinic, though timing varies by program and by state.
Provider access: Telehealth gives you access to licensed providers outside your immediate area. Ask about the provider’s training in weight management and how follow-up works.
Stigma reduction: Some people find it easier to talk about weight from home than in a clinic.
Program options to review
Transformation Health is an independent guide. It does not prescribe, sell, or ship medication, and it does not run a weight management program. If you are comparing options, the main types to review are:
- Brand-name medication through insurance: coverage depends on your plan and may require prior authorization.
- Manufacturer self-pay programs: some manufacturers sell certain brand-name doses directly to people paying cash, with a prescription.
- Cash-pay telehealth programs: some prescribe brand-name medication, some prescribe compounded medication, and what the fee includes varies.
- In-person care: a primary care provider, an obesity medicine specialist, or a community health center.
For any of these, ask whether a licensed provider reviews your health history, how lab work is handled, which pharmacy fills the prescription, and what the total cost is over several months, including dose increases.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] Emmerich SD, Fryar CD, Stierman B, Ogden CL. “Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.” NCHS Data Brief No. 508. National Center for Health Statistics, September 2024. Accessed 2026-10-16. https://www.cdc.gov/nchs/products/databriefs/db508.htm
[2] Hales CM, Carroll MD, Fryar CD, Ogden CL. “Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018.” NCHS Data Brief No. 360. National Center for Health Statistics, February 2020. Accessed 2026-10-16. https://www.cdc.gov/nchs/products/databriefs/db360.htm
[3] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Overweight and Obesity Statistics” (2017-2018 NHANES data). Accessed 2026-10-16. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity
[4] Centers for Disease Control and Prevention. “Adult Obesity Prevalence Maps” (2025 BRFSS data; updated September 24, 2026) and data table “Prevalence of Obesity Based on Self-Reported Weight and Height by State and Territory, BRFSS, 2025.” Accessed 2026-10-16. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html
[5] NIDDK. “Health Risks of Overweight and Obesity.” Accessed 2026-10-16. https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks
[6] Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. PMID: 33760880. Cited by CDC, “Adult Obesity Facts.” https://www.cdc.gov/obesity/adult-obesity-facts/index.html
[7] Novo Nordisk. WEGOVY (semaglutide) injection and tablets, Prescribing Information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[8] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, Prescribing Information. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. They may differ in formulation, purity, and potency. Results vary. Prevalence statistics are drawn from CDC surveillance data and are subject to revision as new data becomes available. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.